Safety and Efficacy Study of MT-2990 in Women With Endometriosis

• Status: Active, not recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to assess the safety and efficacy of MT-2990 for treatment of moderate to severe endometriosis-related pain in women with surgically diagnosed endometriosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.

Criteria

Inclusion Criteria:

• Provide written informed consent to participate in this study

• Agree to approximately 30-90 day washout interval of hormonal therapies, if applicable

• Have a history of regular menstrual cycles

• Have a body mass index < 45 kg/m^2 (inclusive)

• Have documented surgical/laparoscopy diagnosis of endometriosis with 10 years

• Agree to use 2 forms of nonhormonal contraception throughout the study

• In the Investigator's opinion, subject is able to understand the nature of the study and any risk involved in participation, and is willing to cooperate and comply with the protocol restrictions and requirements including transvaginal ultrasound.

• Have moderate to severe endometrial related pain

Exclusion Criteria:

• Subject is pregnant, breast feeding, or planning a pregnancy.

• Subject is < 6 months postpartum, postabortion, or post-pregnancy.

• Willing to remove a hormonal intrauterine device (IUD) at least 30 days prior to screening. (Non hormonal IUDs do not have to be removed)

• AST, ALT, or total bilirubin ≥ 2.0 × upper limit of normal (ULN) above the reference range

• Have immunosuppression due to underlying medical condition

• QTcF or QTcB ≥ 450 msec or clinically important abnormal findings on the ECG

• Subject is not up-to-date on breast screening according to current guidelines.

• Has a surgical history of hysterectomy, bilateral oophorectomy and any other recent major surgery

• Subject is required more than 2 weeks of continuous use of prohibited long-acting narcotic or immediate release narcotic for treatment of endometriosis-associated pain.

• Have chronic pelvic pain for nonendometriosis related causes, which require systemic pharmaceutical chronic therapy for pain

• Have other chronic pain syndrome which require chronic analgesic or other chronic therapy

• Have a clinically significant gynecologic condition identified on the TVU (e.g., complex ovarian cyst > 3 cm or simple ovarian cyst > 5 cm, clinically significant endometrial pathology, single fibroid ≥ 4 cm or multiple (> 4) fibroids that measure ≥ 2 cm or symptomatic submucosal fibroid of any size

• Have a current history of undiagnosed abnormal genital bleeding